- VYNE Therapeutics Inc (NASDAQ:VYNE) announced new preclinical data showing the effect of its novel pan-BET inhibitor, VYN201, in a preclinical model of idiopathic pulmonary fibrosis (IPF).
- VYN201 at 0.5 mg/ml and 1 mg/ml demonstrated statistically significant reductions in Ashcroft scores (a measurement of lung fibrosis) and levels of the tissue fibrosis biomarker compared to the placebo control group.
- Also Read: VYNE Therapeutics Touts Encouraging Pharmacokinetic, Hematology Data From Potential Candidate For Skin Disorder.
- Mean control-adjusted lung fibrosis scores for VYN201 1 mg/ml were 65.8% lower than the placebo control group.
- VYN201 demonstrated a dose-dependent improvement in blood oxygen saturation.
- The mean blood oxygen saturation for the VYN201 1 mg/ml group was 92.4%, an 8.8% improvement compared to the placebo group (83.6%). The mean blood oxygen saturation for the untreated and unstimulated control group was 95.2%.
- Treatment with VYN201 1 mg/ml resulted in a 51.8% mean improvement in functional lung volume compared to animals receiving placebo treatment.
- Price Action: VYNE shares are up 48.2% at $4.64 on the last check Wednesday.
Baozun Q3 Total GMV +15.9% YoY To RMB18.63B, Distribution GMV -28.8% YoY To RMB559M
Third Quarter 2022 Operational Highlights
Total Gross Merchandise Volume ("GMV")6 was RMB18,632.1 million, an increase of 15.9% year-over-year.
Distribution GMV7 was RMB559.0 million, a decrease of 28.8%
